CytomX Therapeutics, Inc.
NASDAQCytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other. CytomX announced an expansion of its strategic research collaboration with Regeneron on June 3, targeting conditional bispecific therapeutics for cancer treatment in a deal framed at $4 billion in potential value. The…
Snapshot as of 3 Jun 2026
CytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other. CytomX announced an expansion of its strategic…
CytomX Therapeutics enters today's earnings print carrying its heaviest short position in months — a setup that sharpens the stakes around CX-2051 clinical progress considerably. Short sellers have made a decisive move…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTMX — free to start on ORTEX.
Sign up for free →Open CTMX on ORTEX